

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

REGENERON
SCIENCE TO MEDICINE®

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as *VelociSuite*®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on [LinkedIn](#), [Instagram](#), [Facebook](#) or [X](#).

General Company Information

- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 13,400 employees in the U.S., Canada, UK, EU and Asia
- 2023 R&D investment of \$4.4 billion




Locations

- Tarrytown, NY: Corporate and Research & Development headquarters
- Dublin, Ireland: European headquarters
- Rensselaer, NY and Limerick, Ireland: Industrial Operations and Product Supply facilities
- U.S. offices in New York, New Jersey, Washington, D.C., Massachusetts and California
- Global offices in Canada, Netherlands, United Kingdom, Germany, France, Italy, Spain, Switzerland, India, Japan



Leadership Team

- **Leonard S. Schleifer, MD, PhD**
Board co-Chair, co-Founder, President and Chief Executive Officer
+ *Fellow, American Association for the Advancement of Science (AAAS)*
- **George D. Yancopoulos, MD, PhD**
Board co-Chair, co-Founder, President and Chief Scientific Officer
+ *Member, National Academy of Sciences*
- **Christine A. Poon**
Lead Independent Director
Former Vice Chair, Worldwide Chair of Pharmaceuticals, Member of the Executive Committee and Director at Johnson & Johnson
- **Board of Directors** includes two Nobel Laureates and six members of the National Academy of Sciences



FDA-Approved & Marketed Medicines*



① Commercialized by Kiniksa Pharmaceuticals, Ltd. ② Commercialized with Sanofi. ③ Commercialized by Regeneron in the United States and Ultragenyx Pharmaceuticals Inc. outside the United States. ④ Commercialized by Regeneron in the United States and Bayer outside the United States. ⑤ Commercialized by Regeneron in the United States and Sanofi outside the United States. ⑥ Commercialized by Sanofi.

Clinical Product Candidates

PHASE 1

MIVELSIRAN ^①

RNAi therapeutic targeting APP
Early-onset Alzheimer's disease

ALN-PNP ^②

RNAi therapeutic targeting PNPLA3
NASH

DB-OTO

AAV-based gene therapy
Hearing loss in pediatrics (Phase 1/2)

DUPILUMAB/LINVOSELTAMAB

Antibody to IL-4R / Bispecific antibody
targeting BCMA and CD3 | Severe food allergy

FIANLIMAB

Antibody to LAG-3 | Solid tumors,
advanced hematologic malignancies

NTLA-2001 ^③

TTR gene knockout using CRISPR/Cas9
Transthyretin (ATTR) amyloidosis

ODRONEXTAMAB

Bispecific antibody targeting CD20 and CD3
Certain B-cell malignancies

REGN4336

Bispecific antibody targeting PSMA and CD3
Prostate cancer

DAVUTAMIG

Bispecific antibody targeting
two distinct MET epitopes
MET-altered advanced non-small
cell lung cancer (NSCLC)

REGN5093-M114

Bispecific antibody-drug conjugate targeting
two distinct MET epitopes
MET overexpressing
advanced cancer

REGN5381/REGN9035

Agonist Antibody to NPR1/Reversal
Agent to REGN5381 | NPR1

LINVOSELTAMAB

Bispecific antibody targeting BCMA and CD3
Multiple myeloma

REGN5459

Bispecific antibody targeting BCMA and CD3
Transplant desensitization in patients
with chronic kidney disease

REGN5668

Bispecific antibody targeting MUC16 and CD28
Platinum-resistant ovarian cancer

REGN6569

Antibody to GITR | Solid tumors

REGN7257

Antibody to IL2Rg | Aplastic anemia

REGN7508

Antibody to Factor XI | Thrombosis

REGN7999

Antibody to TMRSS6
Transfusion dependent iron overload

REGN5837

Bispecific antibody targeting CD22 and CD28
B-NHL

Next Generation Covid Antibody

Antibody to SARS-CoV-2 Variants
SARS-CoV-2 Variants

REGN7544

Antagonist antibody to NPR1
Healthy volunteers

REGN13335

Antagonist antibody to PDGF-B
Healthy volunteers

PHASE 2

REGN7075

Bispecific antibody targeting
EGFR and CD28 | Solid tumors

ALN-APP ^②

RNAi therapeutic targeting APP
Cerebral amyloid angiopathy (CAA)

ITEPEEKIMAB ^①

Antibody to IL-33
Non-cystic fibrosis
bronchiectasis (NCFB)

Nezastomig (REGN5678)

Bispecific antibody targeting
PSMA and CD28 | Prostate cancer

Trevogrumab (REGN1033)

Antibody to Myostatin (GDF8)
Healthy volunteers

ALN-HSD

RNAi therapeutic targeting
HSD17B13 | NASH

CEMIPLIMAB

Antibody to PD-1 | Neoadjuvant
cutaneous squamous cell
carcinoma (CSCC); First-line
non-small cell lung cancer
(NSCLC), BNT116 combination

DUPILUMAB ^①

Antibody to IL-4R alpha subunit
Ulcerative colitis; Eosinophilic
gastroenteritis (Phase 2/3)

ODRONEXTAMAB

Bispecific antibody targeting
CD20 and CD3
B-cell non-Hodgkin lymphoma
(B-NHL) (pivotal study)

FIANLIMAB

Antibody to LAG-3
First-line advanced NSCLC
(Phase 2/3) (pivotal study)

MIBAVADEMAB

Agonist antibody to leptin
receptor (LEPR)
Generalized lipodystrophy

REGN5381

Agonist antibody to NPR1
Heart failure

LINVOSELTAMAB

Bispecific antibody targeting
BCMA and CD3 | Multiple
myeloma (pivotal study); earlier
(pre-malignant) multiple myeloma

SARILUMAB ^①

Antibody to IL-6R
Polyarticular-course juvenile
idiopathic arthritis (pJIA) (pivotal
study), systemic juvenile idiopathic
arthritis (SJIA) (pivotal study)

VIDUTOLIMOD

Immune activator targeting TLR9
Solid tumors

UBAMATAMAB

Bispecific antibody targeting
MUC16 and CD3
Platinum-resistant ovarian cancer

REGN9933

Antibody to Factor XI
Thrombosis

PHASE 3

EYLEA HD

(AFLIBERCEPT) 8 MG
VEGF | Retinal vein occlusion (RVO)

CEMIPLIMAB

Antibody to PD-1 | Adjuvant CSCC

DUPILUMAB ^①

IL-4R Alpha Subunit Antibody
Chronic obstructive pulmonary disease
(COPD); bullous pemphigoid; chronic
spontaneous urticaria (CSU); chronic
pruritus of unknown origin; asthma in
pediatrics

FIANLIMAB

Antibody to LAG-3
First-line metastatic melanoma;
First-line adjuvant melanoma

ITEPEKIMAB ^①

IL-33 Antibody | COPD

NTLA-2001

TTR gene knockout using CRISPR/Cas9
Transthyretin amyloidosis with
cardiomyopathy (ATTR-CM)

POZELIMAB

C5 | Myasthenia gravis,
clemastine combination; paroxysmal
nocturnal hemoglobinuria (PNH),
clemastine combination

REGN5713-5714-5715

Multi-antibody therapy to Bet v 1
Birch allergy

GARETOSMAB

Antibody to Activin A
Fibrodysplasia ossificans
progressiva (FOP)

LINVOSELTAMAB

BCMA and CD3 | Multiple myeloma

ODRONEXTAMAB

CD20 and CD3 | Follicular lymphoma (FL);
Diffuse large B-cell lymphoma (DLBCL)

In collaboration with: ^① Sanofi | ^② Bayer | ^③ Intellia | ^④ Alnylam

Ophthalmology Infectious Diseases Immunology & Inflammatory Diseases Oncology Cardiovascular/Metabolic Diseases Hematology Rare Diseases Neurology

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases.

The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Leaders in Technology

Fully human monoclonal antibodies

Regeneron has developed a suite of patented technologies (*VelociSuite*[®]), including *VelociGene*[®], *VelocImmune*[®] and *VelociMab*[®], that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Genetic Medicines technology

We've made significant strides by leveraging our long-standing leadership in antibody technologies, combined with insights from the Regeneron Genetics Center[®] to build a pipeline of genetic medicine spanning multiple therapeutic approaches, including gene silencing, editing and gene therapy. With multiple genetic medicines-based technologies at our fingertips, we now have the potential to address the most promising genetic targets, driving forward scientific progress to change lives.

Regeneron Genetics Center[®]

A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.



LexisNexis: Innovation Momentum – The Global Top 100, 2024
Dow Jones Sustainability World Index, 2023
Dow Jones Sustainability North America Index, 2023
Human Rights Foundation: Corporate Equality Index, 2023
Science: Top Employer, 2023
Fast Company: Best Workplaces for Innovators, 2023
Forbes: America's Best Employers for Women, 2023
Newsweek: America's Greenest Companies, 2023

Disability:IN & American Association of People with Disabilities:
Best Place to Work for Disability Inclusion, 2023
Civic 50: Most Community-Minded Companies in the Nation, 2023
Newsweek: America's Most Responsible Companies, 2023
Biospace: Best Place to Work, 2023
Glassdoor: Best Places to Work, 2023
Newsweek: America's Greatest Workplaces for Diversity, 2023

To learn more about us, please visit:
REGENERON.COM **in** **REGENERON**

Regeneron Genetics Center, Science to Medicine, *VelociGene*, *VelociSuite*, *VelocImmune*, *VelociMab*, Arcalyst, EYLEA and Libtayo are registered trademarks of Regeneron Pharmaceuticals, Inc. in the U.S.; Praluent and Dupixent are registered trademarks of Sanofi. © Regeneron Pharmaceuticals, Inc. 5/24